NeuraLight
NeuraLight develops a software-based AI platform that uses computer vision to extract objective neurological biomarkers from eye-movement video, sold as a B2B SaaS tool to pharmaceutical and biotech companies running clinical trials in Parkinson's, ALS, MS, and Huntington's disease.
- Company typePrivate
- Founded2021
- HeadquartersTel Aviv, Israel
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What NeuraLight does
NeuraLight is a private, venture-backed digital health company founded in 2021 and headquartered in Tel Aviv with U.S. offices in Austin and New York. The company develops a software-based platform that uses proprietary computer vision and machine learning to extract objective neurological biomarkers from eye movements captured via standard webcams and tablets, with a primary focus on neurodegenerative disease assessment in clinical trial settings.
The core product is a three-stage workflow — standardized visual assessment completed in minutes, AI-driven analysis of task performance, and extraction of multiple quantitative biomarkers per session. Its lead biomarker, ASH (Amplitude of Saccadic Hypometria), provides a direct functional readout of basal ganglia circuitry and has been clinically validated across multiple independent cohorts (P-value <0.0001), with the company reporting 10x greater sensitivity than the MDS-UPDRS gold standard in tracking Parkinson's disease progression. The platform is being evaluated across Parkinson's, ALS, MS, PSP, MSA, and Huntington's disease, supported by a portfolio of 12+ peer-reviewed publications and multicenter clinical studies including PALOMA and PARATROOPER.
NeuraLight operates a B2B SaaS model, licensing the platform through direct enterprise sales to pharmaceutical and biotech companies conducting clinical trials, with pricing negotiated per trial or partnership. Customers and partners include Teitur Trophics, Kariya Pharmaceuticals, NeuroSense Therapeutics, and CHDI Foundation. The company is led by co-founders Edmund Ben Ami (CEO) and Gil Shklarski (Scientific Co-founder), with Nobel laureate Prof. Thomas Südhof as Scientific Co-founder and Prof. Olivier Rascol — co-creator of the MDS-UPDRS — heading the Scientific Advisory Board. Total disclosed funding is $30.5M across a $5.5M seed (Oct 2021) and a $25M Series A led by Koch Disruptive Technologies (May 2022).
NeuraLight firmographics
Firmographics- Name
- NeuraLight
- Legal name
- Neuralight, Inc.
- Website
- https://neuralight.ai
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- NeuraLight develops a software-based AI platform that uses computer vision to extract objective neurological biomarkers from eye-movement video, sold as a B2B SaaS tool to pharmaceutical and biotech companies running clinical trials in Parkinson's, ALS, MS, and Huntington's disease.
- Ownership category
- akta.pro rank
NeuraLight industry classification
Industry- Product category
- Clinical Trial Biomarker Software
- NAICS
- Computer Systems Design and Related Services (54151), Other Scientific and Technical Consulting Services (54169)
- SIC
- Services-Computer Integrated Systems Design (7373)
- akta.pro primary industry
- Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables) (HLAHACAE)
- akta.pro secondary industries
- Medical Imaging AI (HDAAAEAH), Real-Time Vision at the Edge (on-device CV/video) (HDAAAJAE), Neuro-Ophthalmology (HLAKAKAH)
Keywords
Where NeuraLight is headquartered
LocationHeadquarters
- HQ city
- Tel Aviv
- HQ country
- Israel
- HQ region
- Middle East
Offices3 records
Markets served
NeuraLight business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations, Others
Revenue model
- Biomarker Platform SaaS Subscription: NeuraLight licenses its precision brain function biomarker platform to pharmaceutical and biotech companies for use in clinical trials. The platform is deployed as a software-as-a-service solution integrated into drug trial protocols to provide quantitative assessment of disease-relevant neural pathway function.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
NeuraLight product offering
Product offeringCore offering
NeuraLight develops a software-based platform that uses proprietary computer vision and machine learning to extract precision biomarkers of brain function from eye movements captured via standard webcams and tablets. The platform delivers standardized visual assessments, AI-driven analysis, and multiple quantitative oculometric biomarkers per session in minutes. It is licensed to pharmaceutical and biotech companies as a SaaS solution for use as objective endpoints in clinical trials for Parkinson's, ALS, MS, Huntington's, PSP, and MSA.
Product overview
NeuraLight offers a unified software-based platform for precision brain function measurement through eye movement analysis. The core NeuraLight Platform uses computer vision and deep learning to extract objective biomarkers from video assessments, with products including the ASH (Amplitude of Saccadic Hypometria) biomarker for Parkinson's disease tracking and the Precision Brain Function Biomarker Platform deployed across multiple neurodegenerative indications (Parkinson's, ALS, MS, PSP, MSA, Huntington's disease). The platform delivers three-stage workflow: Assessment (standardized visual tasks), Analysis (proprietary algorithms), and Results (quantitative biomarker outputs) with 10x sensitivity improvement over traditional clinical scales.
Differentiator
Problem solved
Functional benefit
Products and services
- NeuraLight Platform
- ASH (Amplitude of Saccadic Hypometria) Biomarker
- Precision Brain Function Biomarker Platform
- Neuroprogression Biomarker Readouts
Quantifiable outcome
- 10x greater sensitivity than MDS-UPDRS in tracking Parkinson's disease progression
- +3 more outcomes
Companies that use NeuraLight
Customer profileNamed customers4 records
Segments2 records
Ideal customer profiles2 records
NeuraLight technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature4 records
NeuraLight partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and minor.
- Kariya PharmaceuticalscoreNeuraLight and Kariya Pharmaceuticals partnered to integrate NeuraLight's precision biomarker platform into Kariya's Phase II clinical trial program for KP405, a first-in-class brain-penetrant dual GLP-1/GIP receptor agonist in development for Parkinson's and Alzheimer's disease. NeuraLight's platform will be used to quantify the neuroprotective effect of KP405 and provide objective, quantitative assessment of brain function. KP405 is engineered to cross the blood-brain barrier and reduce neuroinflammation and protect neurons.
- Teitur Trophics ApScoreNeuraLight and Teitur Trophics entered a collaboration granting Teitur Trophics access to NeuraLight's precision brain function biomarker platform for use in Teitur Trophics' upcoming Phase I clinical trial of TT-P34, a novel neuroprotective compound in development for Parkinson's disease. NeuraLight's platform will provide quantitative assessment of disease-relevant neural pathway function to support evaluation of TT-P34's potential as a disease-modifying therapy. TT-P34 is a subcutaneously administered cyclic peptide designed to reactivate CREB signaling and improve lysosomal and mitochondrial function.
- CHDI FoundationcoreNeuraLight and CHDI Foundation, a nonprofit biomedical research organization exclusively dedicated to developing therapeutics for Huntington's disease, announced a collaboration to develop sensitive precision eye movement biomarkers to support Huntington's disease clinical trials. A collaborative study was conducted at the 2025 HDSA Annual Convention in Indianapolis, with NeuraLight building one of the largest eye movement datasets in HD to support the development of trial-ready biomarkers.
- NeuroSense TherapeuticsminorNeuraLight and NeuroSense Therapeutics partnered to advance the development of objective biomarkers for monitoring ALS disease progression. The collaboration aimed to demonstrate that oculometrics provide an objective, reliable, and replicable measure of ALS progression, with goals to improve patient stratification, trial power, and reduce sample sizes and trial duration for ALS drug development programs including PrimeC.
Scale indicators6 records
Recent moves6 records
Expansion highlights6 records
NeuraLight competitors and assessment
Company assessmentDirect peers
- ViewMind: Eye-tracking-based cognitive assessment platform for early detection of CNS disorders including Alzheimer's. Closest peer in oculometric/cognitive biomarker modality for neurodegenerative trials.
- Altoida: Digital neuro biomarker platform using smartphone/AR-based assessments to predict and track cognitive decline, including Alzheimer's and Parkinson's. Most direct peer in digital CNS biomarker SaaS for pharma clinical trials.
- Cumulus Neuroscience: Provides a multi-modal digital biomarker platform (EEG, voice, cognition) for CNS clinical trials in indications such as Alzheimer's and depression. Directly competes for the same pharma trial endpoint budget.
- VivoSense: Digital biomarker company specializing in wearable/sensor-derived endpoints for neurological and rare disease clinical trials. Comparable B2B SaaS model targeting pharma/biotech trial sponsors.
- Cambridge Cognition: Provider of computerized cognitive assessments (e.g., CANTAB) widely used as endpoints in CNS clinical trials across pharma and academic research. Overlapping customer base and use cases with NeuraLight in neuro trials.
- IXICO: Imaging and digital biomarker analytics for neuroscience clinical trials, particularly in Huntington's, Alzheimer's, and other neurodegenerative indications. Competes for the same trial endpoint and patient stratification spend.
Broad incumbents
- Clario: Large clinical trial technology company formed from ERT and Bioclinica, offering eCOA, imaging, and digital endpoint solutions across therapeutic areas. Broad incumbent competing for digital endpoint wallet share in CNS trials.
- Medidata (Dassault Systèmes): Leading clinical trial SaaS platform owned by Dassault Systèmes, increasingly adding sensor- and digital biomarker-derived endpoints. Broad incumbent competing for end-to-end trial data capture in neuro programs.
- Biogen Digital Health: Internal digital health/biomarker arm of major neuroscience-focused pharma Biogen. Represents the in-house alternative that could displace external vendors like NeuraLight on pivotal neuro trials.
Others
- Cerveau Technologies: Provider of tau PET imaging biomarkers used as endpoints in Alzheimer's clinical trials. Adjacent enabling peer in CNS trial endpoints, illustrating an alternative (imaging-based) modality competing for the same trial endpoints.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
NeuraLight social profiles
Digital presenceNeuraLight financial estimates
Financial estimateRevenue estimate
Valuation estimate
NeuraLight leadership team
Management profileNumber of profiles
Profiles18 records
NeuraLight funding detail
Funding detailFunding overview
Funding rounds2 records
Investors12 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
NeuraLight M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about NeuraLight
What does NeuraLight do?
NeuraLight develops a software-based platform that uses proprietary computer vision and machine learning to extract precision biomarkers of brain function from eye movements captured via standard webcams and tablets. The platform delivers standardized visual assessments, AI-driven analysis, and multiple quantitative oculometric biomarkers per session in minutes. It is licensed to pharmaceutical and biotech companies as a SaaS solution for use as objective endpoints in clinical trials for Parkinson's, ALS, MS, Huntington's, PSP, and MSA.
Is NeuraLight a public or private company?
NeuraLight is a private company. It is classified as venture growth investor backed and is currently operating.
When was NeuraLight founded?
NeuraLight was founded in 2021. It employs 11 to 50 people.
Where is NeuraLight based?
NeuraLight is headquartered in Tel Aviv, Israel, in the Middle East region.
How does NeuraLight make money?
One revenue line is on record: biomarker Platform SaaS Subscription.
Who are NeuraLight's main competitors?
Direct peers on record are ViewMind, Altoida, Cumulus Neuroscience, VivoSense, Cambridge Cognition and IXICO. Broad incumbents are Clario, Medidata (Dassault Systèmes) and Biogen Digital Health. Cerveau Technologies is listed as an others.
Does NeuraLight have an API?
No public API is recorded for NeuraLight.
What industry is NeuraLight in?
NeuraLight's product category is Clinical Trial Biomarker Software. Its primary akta.pro industry code is HLAHACAE, Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables), with a secondary code of HDAAAEAH, Medical Imaging AI. Its NAICS code is 54151 and its SIC code is 7373.